Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045359 | 0.83 | PPIA (0.40) | MAPTMEN1LMNAKMT2A | |
| SCHEMBL7044720 | 0.82 | CRHR1 (0.42) | MAPTMEN1LMNAKMT2AHTT | |
| SCHEMBL7043666 | 0.81 | MAPT (0.47) | MAPTLMNAHTT | |
| SCHEMBL7044716 | 0.75 | MAPT (0.42) | MAPTMEN1KMT2A | |
| SCHEMBL7045767 | 0.75 | MAPT (0.37) | MAPTMEN1LMNAKMT2AHTT | |
| SCHEMBL6694814 | 0.70 | CYP1A2 (0.38) | MAPTKDRMEN1LMNAKMT2A | |
| SCHEMBL7043420 | 0.70 | NPC1 (0.43) | MAPTMEN1KMT2A | |
| SCHEMBL7101569 | 0.66 | KMT2A (0.43) | MAPTMEN1LMNAKMT2AHTT | |
| SCHEMBL7046695 | 0.65 | ALDH1A1 (0.34) | MAPTMEN1LMNAKMT2AHTT | |
| SCHEMBL7047413 | 0.65 | PTGS2 (0.37) | MAPTMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002064096-A9 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC (US) | 2003-10-16 | — | — | WO | disclosed |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2002064096-A2 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TYMP, TYMS, NUDT1 | MAPT 2656/4885KDR 2822/4885MEN1 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.